Apoptosis signal-regulating kinase 1 exhibits oncogenic activity in pancreatic cancer
Metrics: PDF 1526 views | HTML 1567 views | ?
Youguang Luo1,2,*, Siqi Gao2,*, Ziwei Hao2, Yang Yang2, Songbo Xie1, Dengwen Li2, Min Liu1, Jun Zhou1,2
1Institute of Biomedical Sciences, College of Life Sciences, Key Laboratory of Animal Resistance Biology of Shandong Province, Key Laboratory of Molecular and Nano Probes of the Ministry of Education, Shandong Normal University, Jinan 250014, China
2State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China
*These authors have contributed equally to this work
Jun Zhou, email: email@example.com
Keywords: pancreatic cancer, ASK1, kinase activity, cell proliferation, cell migration
Received: June 13, 2016 Accepted: September 05, 2016 Published: September 17, 2016
Pancreatic cancer has an extremely grim prognosis, with an overall 5-year survival rate less than 5%, as a result of its rapid metastasis and late diagnosis. To combat this disease, it is crucial to better understand the molecular mechanisms that contribute to its pathogenesis. Herein, we report that apoptosis signal-regulating kinase 1 (ASK1) is overexpressed in pancreatic cancer tissues and that its expression correlates with the histological grade of pancreatic cancer. The expression of ASK1 is also elevated in pancreatic cancer cell lines at both protein and mRNA levels. In addition, ASK1 promotes the proliferation and stimulates the tumorigenic capacity of pancreatic cancer cells. These functions of ASK1 are abrogated by pharmacological inhibition of its kinase activity or by introduction of a kinase-dead mutation, suggesting that the kinase activity of ASK1 is required for its role in pancreatic cancer. However, the alteration of ASK1 expression or activity does not significantly affect the migration or invasion of pancreatic cancer cells. Collectively, these findings reveal a critical role for ASK1 in the development of pancreatic cancer and have important implications for the diagnosis and treatment of this malignancy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.